Global orphan drug market is expected to reach US $112 billion in 2017

2013-08-19 source: according to the market research report entitled "orphan drug market: biotechnology drugs as the center" of BCC research company of Ding Xiangyuan, the United States, in 2011, the global market share of orphan drugs was 82.6 billion US dollars, and in 2012, it was close to 86 billion US dollars Analysts predict that the market share will reach 112 billion in 2017, with a compound annual growth rate of 5.4% Orphan drugs are used for the prevention, treatment and diagnosis of orphan diseases Due to the small number of rare patients, low market demand and high research and development cost, few pharmaceutical companies pay attention to the research and development of their treatment drugs, so these drugs are vividly called "orphan drugs" Generally speaking, orphan disease is a rare disease There is no unified standard for the definition of the prevalence rate of rare diseases in the world The World Health Organization defines the rare disease as the disease or pathological change with the number of patients accounting for 0.65% - 1% of the total population But the concept of orphan disease is broader than that of rare disease, including some diseases that are not rare but neglected by people In order to promote the research and development of orphan drugs, the United States introduced the first orphan drug act in 1983 Other countries have also introduced corresponding orphan drug bills Due to the lack of market demand, before these bills were introduced, only less than 10 orphan drugs were listed, and they were basically not profitable The government's intervention has opened a profit channel for pharmaceutical companies and attracted their interest in research and development The report of BCC research analyzes in detail the markets, drug types (biological drugs, non biological drugs), active ingredients and application fields of orphan drugs in various regions It is pointed out that at present, biological or non biological orphan drugs are mainly distributed in the field of tumor In addition, the report also analyzes the current market value of biological and non biological orphan drugs, the forecast for the future, and the growth rate in the next five years The analysis report shows that the market share of biological orphan drugs in 2012 is US $57.7 billion, which is expected to reach 71.4 billion by 2017, with a compound annual growth rate of 4.3% Meanwhile, the market share of non biological orphan drugs was 28.3 billion in 2012, 40.8 billion in 2017, with a compound annual growth rate of 7.5% The analysis report points out that the main driving factors for the growth of orphan drug market are: R & D, new technology development, increased policy support and new drug listing In addition, the use of drugs outside the approval mark also contributes to market growth What's more, the analysis report deeply interprets the current regulations on orphan drug control, provides clear guidance for the industry, and has important reference value for pharmaceutical, biotechnology companies, research and development institutions, and physicians Source address: http:// HTML? Utm_source = feed